Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Shares Outstanding (Entity) of $71.2 million for Q1 2026, down 1.1% year-over-year from $72.0 million in Q1 2025, and up 3.0% quarter-over-quarter from $69.1 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Shares Outstanding (Entity) history runs 8 years deep, the most recent figure standing at $71.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) fell 1.1% year-over-year to $71.2 million; the TTM figure through Mar 2026 stood at $71.2 million (down 1.1% YoY), while the FY2025 annual figure was $69.1 million, down 3.08% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $71.2 million, up from $69.1 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $72.2 million in Q3 2025, with the low at $45.6 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $70.8 million (2023), against an average of $66.6 million.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) surged 37.88% in 2022, then fell 3.08% in 2025.
- Zentalis Pharmaceuticals' Shares Outstanding (Entity) stood at $59.3 million in 2022, then rose by 19.38% to $70.8 million in 2023, then gained by 0.73% to $71.3 million in 2024, then fell by 3.08% to $69.1 million in 2025, then grew by 3.0% to $71.2 million in 2026.
- Business Quant data shows ZNTL's Shares Outstanding (Entity) at $71.2 million in Q1 2026, $69.1 million in Q4 2025, and $72.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | 71.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.33 Mn |
| Mar 31, 2026 | 70.26 Mn |
| Dec 31, 2025 | 71.87 Mn |
| Sep 30, 2025 | 72.14 Mn |
| Jun 30, 2025 | 71.99 Mn |
| Mar 31, 2025 | 71.68 Mn |
| Dec 31, 2024 | 71.08 Mn |
| Sep 30, 2024 | 71.11 Mn |
| Jun 30, 2024 | 71.04 Mn |
| Mar 31, 2024 | 70.90 Mn |
| Dec 31, 2023 | 65.41 Mn |
| Sep 30, 2023 | 70.61 Mn |
| Jun 30, 2023 | 60.79 Mn |
| Mar 31, 2023 | 59.28 Mn |
| Dec 31, 2022 | 52.86 Mn |
| Sep 30, 2022 | 56.81 Mn |
| Jun 30, 2022 | 51.12 Mn |
| Mar 31, 2022 | 45.24 Mn |
| Dec 31, 2021 | 42.69 Mn |
| Sep 30, 2021 | 44.61 Mn |